212 related articles for article (PubMed ID: 29472801)
1. Diagnostic value of tumour markers in pleural effusions.
Volarić D; Flego V; Žauhar G; Bulat-Kardum L
Biochem Med (Zagreb); 2018 Feb; 28(1):010706. PubMed ID: 29472801
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions.
Korczynski P; Krenke R; Safianowska A; Gorska K; Abou Chaz MB; Maskey-Warzechowska M; Kondracka A; Nasilowski J; Chazan R
Eur J Med Res; 2009 Dec; 14 Suppl 4(Suppl 4):128-33. PubMed ID: 20156743
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
Lee JH; Chang JH
Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions.
Ferrer J; Villarino MA; Encabo G; Felip E; Bermejo B; Vilà S; Orriols R
Cancer; 1999 Oct; 86(8):1488-95. PubMed ID: 10526277
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients.
Ghayumi SM; Mehrabi S; Doroudchi M; Ghaderi A
Pathol Oncol Res; 2005; 11(4):236-41. PubMed ID: 16388321
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
7. Differential diagnosis of tuberculous and malignant pleural effusions: comparison of the Th1/Th2 cytokine panel, tumor marker panel and chemistry panel.
Zhang J; Chen Y; He G; Jiang X; Chen P; Ouyang J
Scand J Clin Lab Invest; 2020 Jul; 80(4):265-270. PubMed ID: 32108543
[TBL] [Abstract][Full Text] [Related]
8. Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers.
Fazli Khalaf F; Asadi Gharabaghi M; Balibegloo M; Davari H; Afshar S; Jahanbin B
Int J Biol Markers; 2023 Jun; 38(2):81-88. PubMed ID: 36942429
[TBL] [Abstract][Full Text] [Related]
9. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
10. Clinical Value of Tumor Markers for Determining Cause of Pleural Effusion.
Gu Y; Zhai K; Shi HZ
Chin Med J (Engl); 2016 Feb; 129(3):253-8. PubMed ID: 26831224
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A
Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016
[No Abstract] [Full Text] [Related]
12. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
Yang Q; Zhang P; Wu R; Lu K; Zhou H
Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature.
Shitrit D; Zingerman B; Shitrit AB; Shlomi D; Kramer MR
Oncologist; 2005 Aug; 10(7):501-7. PubMed ID: 16079317
[TBL] [Abstract][Full Text] [Related]
16. Tumor markers in pleural effusions.
Topolcan O; Holubec L; Polivkova V; Svobodova S; Pesek M; Treska V; Safranek J; Hajek T; Bartunek L; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1921-4. PubMed ID: 17649796
[TBL] [Abstract][Full Text] [Related]
17. Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer.
Gwak HK; Lee JH; Park SG
Asian Pac J Cancer Prev; 2014; 15(12):4933-8. PubMed ID: 24998567
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer.
Wu GP; Ba J; Zhao YJ; Wang EH
Acta Cytol; 2007; 51(4):679-80. PubMed ID: 17718156
[No Abstract] [Full Text] [Related]
19. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions.
Alataş F; Alataş O; Metintaş M; Colak O; Harmanci E; Demir S
Lung Cancer; 2001 Jan; 31(1):9-16. PubMed ID: 11162861
[TBL] [Abstract][Full Text] [Related]
20. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]